Status: Recruiting
A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of single ascending oral doses(SAD) of PG-033 by directly comparing it with placebo. Meanwhile, the impact of a high-fat meal on the pharmacokinetics of PG-033 will also be evaluated. The research will also explore the potential metabolites and metabolic pathways of PG-033 within the human body，as well as investigate the effect of PG-033 on the QTc interval.
Participants needed: 52
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Prime Gene Therapeutics Co., Ltd.Updated: Jun 2, 2026Locations: 1
Eligibility criteria
1. Read, understood, and signed an ICF before any investigational procedure(s) a...
1. Participants with abnormal electrocardiogram results during screening (e.g.,...